直接转运至具备取栓能力中心与当地卒中中心对疑似大血管闭塞卒中患者神经功能结局的影响:RACECAT随机临床试验
在西班牙加泰罗尼亚非城市地区开展的多中心、基于人群的整群随机试验,纳入1401例疑似急性大血管闭塞卒中患者,比较直接转运至具备取栓能力中心与转运至最近当地卒中中心。结果显示目标缺血性卒中人群90天改良Rankin量表评分中位数两组均为3分(调整共同OR 1.03;95%CI 0.82-1.29),无显著差异;直接转运组静脉组织型纤溶酶原激活剂给药率更低、取栓率更高,90天死亡率无显著差异。
要点
- 非城市地区疑似大血管闭塞卒中患者,直接转运至取栓中心与当地卒中中心90天神经功能结局无显著差异。
- 直接转运至取栓中心组静脉溶栓率更低(47.5% vs 60.4%;OR 0.59;95%CI 0.45-0.76)。
- 直接转运至取栓中心组取栓率更高(48.8% vs 39.4%;OR 1.46;95%CI 1.13-1.89)。
核心结论
- 在西班牙加泰罗尼亚非城市地区,疑似大血管闭塞卒中患者直接转运至具备取栓能力中心与转运至当地卒中中心相比,90天神经功能结局无显著差异。
- 这些发现需要在其他环境中重复验证。
研究设计与样本
- 多中心、基于人群的整群随机试验,于2017年3月至2020年6月在西班牙加泰罗尼亚开展,最终随访日期为2020年9月。
- 纳入1401例由急救医疗服务接诊的疑似急性大血管闭塞卒中患者,所在地区最近当地卒中中心不具备取栓能力。
- 干预为转运至具备取栓能力中心(n=688)或最近当地卒中中心(n=713)。
- 1401例纳入安全性分析,其中1369例(98%)同意参与并纳入按随机化分析(56%男性;中位年龄75岁[IQR 65-83];中位美国国立卫生研究院卒中量表评分17[IQR 11-21]);949例(69%)构成目标缺血性卒中人群并纳入主要分析。
- 第二次中期分析后因无效而停止入组。
主要发现
- 目标人群主要结局:90天改良Rankin量表评分中位数两组均为3分(IQR 2-5),调整共同OR 1.03;95%CI 0.82-1.29。
- 11项报告的次要结局中8项无显著差异。
- 目标人群静脉组织型纤溶酶原激活剂给药:直接转运至取栓中心组229/482(47.5%)vs 转运至当地卒中中心组282/467(60.4%);OR 0.59;95%CI 0.45-0.76。
- 目标人群取栓:直接转运至取栓中心组235/482(48.8%)vs 转运至当地卒中中心组184/467(39.4%);OR 1.46;95%CI 1.13-1.89。
- 安全性人群90天死亡率:直接转运至取栓中心组188/688(27.3%)vs 转运至当地卒中中心组194/713(27.2%);调整风险比0.97;95%CI 0.79-1.18,两组无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 第二次中期分析后因无效而停止入组。
- 这些发现需要在其他环境中重复验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In nonurban areas with limited access to thrombectomy-capable centers, optimal prehospital transport strategies in patients with suspected large-vessel occlusion stroke are unknown. OBJECTIVE: To determine whether, in nonurban areas, direct transport to a thrombectomy-capable center is beneficial compared with transport to the closest local stroke center. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, population-based, cluster-randomized trial including 1401 patients with suspected acute large-vessel occlusion stroke attended by emergency medical services in areas where the closest local stroke center was not capable of performing thrombectomy in Catalonia, Spain, between March 2017 and June 2020. The date of final follow-up was September 2020. INTERVENTIONS: Transportation to a thrombectomy-capable center (n = 688) or the closest local stroke center (n = 713). MAIN OUTCOMES AND MEASURES: The primary outcome was disability at 90 days based on the modified Rankin Scale (mRS; scores range from 0 [no symptoms] to 6 [death]) in the target population of patients with ischemic stroke. There were 11 secondary outcomes, including rate of intravenous tissue plasminogen activator administration and thrombectomy in the target population and 90-day mortality in the safety population of all randomized patients. RESULTS: Enrollment was halted for futility following a second interim analysis. The 1401 enrolled patients were included in the safety analysis, of whom 1369 (98%) consented to participate and were included in the as-randomized analysis (56% men; median age, 75 [IQR, 65-83] years; median National Institutes of Health Stroke Scale score, 17 [IQR, 11-21]); 949 (69%) comprised the target ischemic stroke population included in the primary analysis. For the primary outcome in the target population, median mRS score was 3 (IQR, 2-5) vs 3 (IQR, 2-5) (adjusted common odds ratio [OR], 1.03; 95% CI, 0.82-1.29). Of 11 reported secondary outcomes, 8 showed no significant difference. Compared with patients first transported to local stroke centers, patients directly transported to thrombectomy-capable centers had significantly lower odds of receiving intravenous tissue plasminogen activator (in the target population, 229/482 [47.5%] vs 282/467 [60.4%]; OR, 0.59; 95% CI, 0.45-0.76) and significantly higher odds of receiving thrombectomy (in the target population, 235/482 [48.8%] vs 184/467 [39.4%]; OR, 1.46; 95% CI, 1.13-1.89). Mortality at 90 days in the safety population was not significantly different between groups (188/688 [27.3%] vs 194/713 [27.2%]; adjusted hazard ratio, 0.97; 95% CI, 0.79-1.18). CONCLUSIONS AND RELEVANCE: In nonurban areas in Catalonia, Spain, there was no significant difference in 90-day neurological outcomes between transportation to a local stroke center vs a thrombectomy-capable referral center in patients with suspected large-vessel occlusion stroke. These findings require replication in other settings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02795962.
引用
- Pérez de la Ossa N, Abilleira S, Jovin TG, et al. Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial. JAMA. 2022. PMID: 35510397. doi:10.1001/jama.2022.4404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。